Achieving an animal free IHC | Laboratory News
With alternative technologies available, we should be seeking antibody alternatives that avoid the unnecessary use of animals in research, urges Dr Davi...
Stay updated with breaking news from David Bunka. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
With alternative technologies available, we should be seeking antibody alternatives that avoid the unnecessary use of animals in research, urges Dr Davi...
Aptamer Group PLC on Thursday announced a cost-cutting drive as it aims to break even within two years. The York-based biotech firm that makes synthetic antibodies capable of binding to targets such...
The former chief executive and chairman of Aptamer Group have returned to take control of the York-based biotech company after months of turmoil.
Sale process ends as AIM-listed group's board resigns
Oligonucleotide affinity ligands developer Aptamer Group has developed a panel of binders to a novel Alzheimer’s disease biomarker, patented by partners at Neuro-Bio, following the demonstration of performance in specifically binding to the target biomarker and functionality in a nasal mucous matrix. Click to read more...